multivalent pneumococcal conjugate vaccine + PF-07872411

This drug is a **combination of a multivalent pneumococcal conjugate vaccine** with **PF-07872411**, a novel immunostimulant adjuvant developed by Pfizer. The addition of PF-07872411 is intended to enhance the immunogenicity of the multivalent pneumococcal conjugate vaccine, which targets multiple serotypes of *Streptococcus pneumoniae*. This vaccine-adjuvant formulation is being investigated primarily for the prevention of diseases caused by *Streptococcus pneumoniae*, such as meningitis, sepsis, sinusitis, and otitis media, in adults aged 50–64. PF-07872411 acts as an immunostimulant, likely modulating or boosting innate and adaptive immune responses to the conjugated polysaccharide antigens in the vaccine. The vaccine is administered intramuscularly and is intended for prophylactic (preventive) use against pneumococcal disease[1][2][3][5].

Other names

multivalent pneumococcal conjugate vaccine with PF-07872411